Pharvaris initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald last night initiated coverage of Pharvaris (PHVS) with an Overweight rating and $28 price target Deucrictibant’s Phase 2 data look stronger than the only approved oral hereditary angioedema long-term prophylaxis therapy, Orladeyo, the analyst tells investors in a research note. The firm believes on-demand deucrictibant is a “meaningful opportunity” and could be a “pipeline-in-a-product” for angioedema, irrespective of the etiology. Pharvaris is a “major player to watch and own in HAE and angioedema broadly,” contends the firm.